Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$110.76 USD
-0.53 (-0.48%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $110.81 +0.05 (0.05%) 6:48 PM ET
3-Hold of 5 3
A Value C Growth D Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
JAZZ 110.76 -0.53(-0.48%)
Will JAZZ be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for JAZZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JAZZ
Is Vident International Equity Strategy ETF (VIDI) a Strong ETF Right Now?
FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up
JAZZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Jazz (JAZZ) Up 1.1% Since Last Earnings Report?
Alkermes (ALKS) Begins Narcolepsy Type 2 Study on ALKS 2680
Axsome (AXSM) Banks on Auvelity & Sunosi to Fuel Growth
Other News for JAZZ
Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst
Jazz Pharmaceuticals (JAZZ) Gets a Buy from Truist Financial
Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024
Jazz Pharmaceuticals presents updated Phase 2 data for zanidatamab
Stock moves reflect downgrade for US economic growth outlook - Goldman